These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2390138)

  • 1. Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia.
    De Knijff P; Stalenhoef AF; Mol MJ; Gevers Leuven JA; Smit J; Erkelens DW; Schouten J; Frants RR; Havekes LM
    Atherosclerosis; 1990 Jul; 83(1):89-97. PubMed ID: 2390138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of specific mutations at the LDL-receptor gene locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolaemia.
    Jeenah M; September W; Graadt van Roggen F; de Villiers W; Seftel H; Marais D
    Atherosclerosis; 1993 Jan; 98(1):51-8. PubMed ID: 8457250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism.
    Carmena R; Roederer G; Mailloux H; Lussier-Cacan S; Davignon J
    Metabolism; 1993 Jul; 42(7):895-901. PubMed ID: 8345800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of apolipoprotein E phenotype on the response to lovastatin therapy in patients with heterozygous familial hypercholesterolemia.
    O'Malley JP; Illingworth DR
    Metabolism; 1990 Feb; 39(2):150-4. PubMed ID: 2299987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia.
    Ojala JP; Helve E; Ehnholm C; Aalto-Setälä K; Kontula KK; Tikkanen MJ
    J Intern Med; 1991 Nov; 230(5):397-405. PubMed ID: 1940775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of LDL receptor gene mutation and apo E polymorphism on lipoprotein response to simvastatin treatment among adolescents with heterozygous familial hypercholesterolemia.
    Vohl MC; Szots F; Lelièvre M; Lupien PJ; Bergeron J; Gagné C; Couture P
    Atherosclerosis; 2002 Feb; 160(2):361-8. PubMed ID: 11849659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statin therapy in a kindred with both apolipoprotein B and low density lipoprotein receptor gene defects.
    Raal FJ; Pilcher G; Rubinsztein DC; Lingenhel A; Utermann G
    Atherosclerosis; 1997 Feb; 129(1):97-102. PubMed ID: 9069523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia.
    Couture P; Brun LD; Szots F; Lelièvre M; Gaudet D; Després JP; Simard J; Lupien PJ; Gagné C
    Arterioscler Thromb Vasc Biol; 1998 Jun; 18(6):1007-12. PubMed ID: 9633944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One year experience in the treatment of familial hypercholesterolaemia with simvastatin.
    Quiney J; Watts GF; Kerr-Muir M; Slavin B; Lewis B
    Postgrad Med J; 1992 Jul; 68(801):575-80. PubMed ID: 1437957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications.
    Watts GF; Cummings MH; Umpleby M; Quiney JR; Naoumova R; Thompson GR; Sönksen PH
    Eur J Clin Invest; 1995 Aug; 25(8):559-67. PubMed ID: 7589011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia.
    Heath KE; Gudnason V; Humphries SE; Seed M
    Atherosclerosis; 1999 Mar; 143(1):41-54. PubMed ID: 10208479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of Simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolaemia.
    Human JA; Ubbink JB; Jerling JJ; Delport R; Vermaak WJ; Vorster HH; Lagendijk J; Potgieter HC
    Clin Chim Acta; 1997 Jul; 263(1):67-77. PubMed ID: 9247729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
    Bruckert E; De Gennes JL; Malbecq W; Baigts F
    Clin Cardiol; 1995 Nov; 18(11):621-9. PubMed ID: 8590530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Similar response to simvastatin in patients heterozygous for familial hypercholesterolemia with mRNA negative and mRNA positive mutations.
    Sijbrands EJ; Lombardi MP; Westendorp RG; Leuven JA; Meinders AE; Van der Laarse A; Frants RR; Havekes LM; Smelt AH
    Atherosclerosis; 1998 Feb; 136(2):247-54. PubMed ID: 9543095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of apolipoprotein E genotypes on plasma lipid and lipoprotein concentrations: results from a segregation analysis in pedigrees with molecularly defined familial hypercholesterolemia.
    Friedlander Y; Leitersdorf E
    Genet Epidemiol; 1996; 13(2):159-77. PubMed ID: 8722744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein E polymorphism and heterozygous familial hypercholesterolemia. Sex-specific effects.
    Ferrières J; Sing CF; Roy M; Davignon J; Lussier-Cacan S
    Arterioscler Thromb; 1994 Oct; 14(10):1553-60. PubMed ID: 7918304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterozygous familial hypercholesterolaemia: the influence of the mutation type of the low-density-lipoprotein receptor gene and PvuII polymorphism of the normal allele on serum lipid levels and response to lovastatin treatment.
    Vuorio AF; Ojala JP; Sarna S; Turtola H; Tikkanen MJ; Kontula K
    J Intern Med; 1995 Jan; 237(1):43-8. PubMed ID: 7830029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to cholesterol-lowering drugs in familial defective apolipoprotein B-100.
    Maher VM; Gallagher JJ; Thompson GR; Myant NB
    Atherosclerosis; 1991 Nov; 91(1-2):73-6. PubMed ID: 1811555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Simvastatin in the treatment of familial hypercholesterolemia].
    Ceska R; Sobra J; Procházková R; Kvasilová M
    Cas Lek Cesk; 1995 May; 134(10):310-3. PubMed ID: 7788650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.
    Naoumova RP; Marais AD; Mountney J; Firth JC; Rendell NB; Taylor GW; Thompson GR
    Atherosclerosis; 1996 Jan; 119(2):203-13. PubMed ID: 8808497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.